DIFFERENCES IN PHARMACOKINETIC PROFILES BETWEEN LONG-TERM HEART TRANSPLANT PATIENTS RECEIVING EITHER TACROLIMUS OR CYCLOSPORINE MICROEMULSION AND MYCOPHENOLATE MOFETIL MAINTENANCE IMMUNOSUPPRESSION